Interesting News

aritcles[0].caption
Nov 16, 2026

EU imposes up to 9.5% anti-dumping duties on Indian steelmakers

The European Commission said the duties follow an investigation into steel pricing and will cover imports from five countries


article.head.headline
Nov 16, 2026
Meganet Technologies Global files draft papers for ₹740-crore IPO

The AI infrastructure provider supplies servers for high-performance computing, data centres and AI workloads, with customers including Yotta and Motilal Oswal

article.head.headline
Nov 16, 2026
Nvidia earnings spotlight shifts to leadership, AI financing after Huang exit

Nvidia faces uncertainty following CEO Jensen Huang's departure due to personal controversies and crisis in leadership. Interim CEO Colette Kress is tasked with addressing concerns over Nvidia's impact on the AI ecosystem. Investors are eager for clarity regarding revenue expectations and ongoing financing commitments in the upcoming earnings report. Key numbers to watch include contributions from the new Vera Rubin data center platform.

article.head.headline
Nov 16, 2026
Barclays lowers 2027 year-end target for S&P 500 index to 8,700

On Monday, Barclays revised its S&P 500 index target for the 2027 year-end from 8,800 to 8,700. The adjustment reflects concerns regarding higher interest rates impacting financial conditions. Analysts believe that tighter financial conditions may lead to increased valuation dips. Strategies suggested by Barclays indicate limited potential for valuation expansion moving forward. Analysts emphasize careful monitoring of the evolving financial landscape in the coming years.

article.head.headline
Nov 16, 2026
US stocks: Summit shares drop after US FDA declines to approve lung cancer drug

Summit Therapeutics faced a notable decline in share value following the FDA's ruling on ivonescimab, which revealed insufficient overall survival benefits during late-stage trials. Despite Summit's emphasis on regional survival differences, analysts worry that this decision could have repercussions for similar treatments in development. Investors now eagerly await new trial results comparing ivonescimab with conventional lung cancer therapies.


Recent News

YOUR NEWS, OUR NETWORK.

Do you have Great News you want to tell the world?

Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.

Morning Dispatcher

Get all the up-to-date breaking news about politics, business, entertainment, sports, lifestyles, weather, traffic, and local news in a seamless digital environment only in Morning Dispatcher.